NYU Langone Health — New York, New York

Public research footprint of NYU Langone Health, compiled from the ClinicalTrials.gov public registry.

1,016

Registered studies

553

Active

335

Recruiting now

304

Completed

137

Stopped or withdrawn

Most-studied conditions

PDAC - Pancreatic Ductal Adenocarcinoma · Glioblastoma · Carcinoma, Non-Small-Cell Lung · Pancreatic Cancer Metastatic

Recently updated registry entries

NCT06741969 — Nipocalimab in Moderate to Severe Sjogren's Disease (Active Not Recruiting)
NCT07573215 — Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic… (Available)
NCT04640623 — A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at NYU Langone Health?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.